Results 31 to 40 of about 22,651 (250)
Choroid Plexus Enlargement and USPIO‐Based Inflammatory Feature in Cerebral Small Vessel Disease
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective The choroid plexus (CP) is a key component of the blood–cerebrospinal fluid barrier (BCSFB), but its mechanism of action in cerebral small vessel disease (CSVD) remains unclear. This study investigated CP volume (CPV) alterations and their association with conventional imaging markers in CSVD and explored the underlying role of ...
Yongqiang Qu +11 more
wiley +1 more source
SPMS: Strand based Persistent Memory System
, 2017 Emerging non-volatile memories enable persistent memory, which offers the opportunity to directly access persistent data structures residing in main memory. In order to keep persistent data consistent in case of system failures, most prior work relies on
Peng Wang +9 more
core +1 more source
International Journal of Emergency Medicine, 2019 Background Subcutaneous penile modifications (SPMs) are more prevalent in Southeast Asian culture and have been growing in popularity in Western culture.
Cali L. Kirkham +2 more
doaj +1 more source
Journal of Medical Internet Research, 2020 BackgroundDefining the transition from relapsing-remitting multiple sclerosis (RRMS) to secondary progressive multiple sclerosis (SPMS) can be challenging and delayed. A digital tool (MSProDiscuss) was developed to facilitate physician-patient discussion
Ziemssen, Tjalf +10 more
doaj +1 more source
Association Between Motor Pathway Damage and Motor Deficit in Upper and Lower Limb in People With MS
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Corticospinal tract damage is common in people with MS, but the degree of clinical symptoms varies. We hypothesize that corticospinal tract lesions are more extensive and severe in people with MS with motor impairments in both upper and lower limbs.
Mathilde Liffran +13 more
wiley +1 more source
Lipid analyses of cholesterol and sphingomyelin of SPMs.
, 2015 A, Cholesterol level of SPMs. A, The cholesterol level of SPMs was determined by the cholesterol oxidase method using an Amplex-Red cholesterol assay kit. B, Composition of sphingomyelins of SPMs.
Akemi Suzuki (142229) +8 more
core +1 more source
Comparison of disease activity in SPMS and PPMS in the context of multicenter clinical trials. [PDF]
, 2012 BACKGROUND: Retrospective single center natural history studies have shown that times to reach disability milestones and ages at which they are reached are similar in primary (PPMS) and secondary (SPMS) progressive multiple sclerosis suggesting that they
Zhenming Zhao +4 more
core +1 more source
Journal of Lipid Research, 2015 Specialized proresolving mediators (SPMs) induce resolution of inflammation. SPMs are derivatives of n-3 and n-6 PUFAs and may mediate their beneficial effects. It is unknown whether supplementation with PUFAs influences the production of SPMs. Alzheimer'
Xiuzhe Wang +8 more
doaj +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective To investigate which baseline clinical and imaging characteristics best predict TSPO‐PET‐measurable reduction in glial activation following treatment of multiple sclerosis (MS), to utilize this information for designing more efficient biomarker‐based clinical trials targeting glial activation.
Marlene T. Morch +5 more
wiley +1 more source
, 2016 Boxplots of age at first symptom in CIS, RRMS-SPMS (combined) and PPMS patients, together with age at onset of progression in SPMS patients.
Giulio Disanto (125817) +25 more
core +1 more source